AstraZeneca Announces Establishment of Northern China Headquarters in Beijing to Deepen Comprehensive Strategic Layout

Today (September 23), AstraZeneca, a global leader in biopharmaceuticals, announced the establishment of its Northern China Headquarters in the Beijing Economic-Technological Development Area. This move signifies that AstraZeneca will further deepen its comprehensive strategic layout in China by adopting a regional headquarters model, marking a milestone of significant importance for the future formation of a multi-headquarters structure in China. Yang Xiuling, Deputy Secretary-General of the Beijing Municipal People's Government; Wang Shaofeng, Secretary of the Working Committee of the Beijing Economic-Technological Development Area; Pascal Soriot, Global CEO of AstraZeneca; and Huang Bin, Vice President of AstraZeneca China and Head of Corporate Affairs and Market Access, all attended and witnessed the strategic signing ceremony.

Subject to obtaining the permits and approvals required by relevant laws and regulations, AstraZeneca’s Northern Headquarters will assume headquarters functions, including operations management, sales and marketing, logistics and distribution, and new drug research and development. Leveraging Beijing’s status as the national political, economic, and cultural center, as well as its influence and gateway role in surrounding regions, the Northern Headquarters will further extend the benefits of AstraZeneca’s innovative medicines and integrated, full-course disease management solutions to patients in northern China.

Following the establishment of AstraZeneca’s Northern China Headquarters, AstraZeneca China will continue to increase its investment in the northern region, building a Northern Commercial Innovation Center at the headquarters to foster the emergence of more smart healthcare innovative solutions in the Beijing Economic-Technological Development Area, jointly enhancing the comprehensive competitiveness of the northern region in the Internet of Medical Things (IoMT) sector. Meanwhile, the Beijing Economic-Technological Development Area will collaborate with AstraZeneca to establish a Sino-British Cooperation Demonstration Park, introducing resources from the UK and globallyHealthcareLeveraging resources and advanced technologies to create a successful model of collaboration and mutual benefit between China and the UK in the healthcare sector.

In response, Pascal Soriot, Global CEO of AstraZeneca, stated: “China is AstraZeneca’s most important strategic market. The strategic decision to establish our Northern China Headquarters in Beijing underscores AstraZeneca’s firm commitment to being rooted in China and delivering long-term benefits to Chinese patients. The development of the Northern China Headquarters relies on the trust and support of the government and various partners. Looking ahead, AstraZeneca will decentralize more headquarters functions and high-quality resources to Beijing to support the growth of the Northern China Headquarters, ensuring that our innovative medicines and integrated diagnostic-therapeutic solutions reach patients across northern China in a more timely manner, thereby contributing to the friendly cooperative relationship between China and the United Kingdom.”

AstraZeneca’s strategic upgrade to establish Beijing as its Northern Headquarters, involving the allocation of substantial high-quality resources and the assignment of multiple key regional headquarters functions, further clarifies its strategic deployment of Beijing as the core of AstraZeneca China’s development, aiming to better address the significant unmet medical needs of patients in the northern regions centered on Beijing.

Lei Wang, Executive Vice President of AstraZeneca and President of International Business and China, stated: “The establishment of the Northern Headquarters marks a significant milestone in AstraZeneca’s comprehensive strategic layout in China. Actively responding to the Healthy China 2030 initiative, AstraZeneca is committed to providing high-quality, standardized medical services to patients across China. In the future, the Northern Headquarters will also serve as our most important strategic base, shouldering the critical mission of realizing AstraZeneca’s ambitions and fulfilling its commitments to patients in the northern region.”